These results collectively suggest that INAVA inhibits HMGA2pS105 level to promote HMGA2‐mediated STAT3 transcriptional activation, consequently inducing NOF activation, which contributes to poorer prognosis in patients with ovarian cancer. The gene discussed is STAT3; the disease is ovarian carcinoma.